NCT07625280Phase 3Recruiting

A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH

Study sponsor: Jazz Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-12-23Estimated
Enrollment · participants120Estimated
Source updated2026-11-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Planned enrollment increased by 12 participants

Before: 108 participants (planned). After: 120 participants (planned).

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source